The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio.

ABSTRACT: Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of dabigatran in fixed-dosing regimens has indicated a small subgroup of patients that could be either over-treated, risking bleeding, or under-treated, risking embolism. Additional post-marketing data lends support to the favorable therapeutic profile of dabigatran but at the same time raises doubts about patient characteristics such as weight, age, renal function and their pharmacokinetic effects that, in some cases, could be serious enough to expose a minority of patients to risk. We will present a clinical case of a patient with an ischem

SUBMITTER: Safouris A 

PROVIDER: S-EPMC4643866 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature